Similarly, advanced urothelial carcinoma patients in low MLDPS group exhibited better prognosis after PD-L1 therapy in the IMvigor 210 cohort (p = 0.012, Fig. 7H). The gene discussed is CD274; the disease is urothelial carcinoma.